Two studies led by Cleveland Clinic researchers found that a variant in a gene involved in androgen synthesis can help predict response to different prostate cancer therapies.
The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.
The firm plans to develop and evaluate the utility of an ethnically diverse group of metastatic prostate cancer patient-derived xenograft models.
The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.
The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
The genomic test is designed to help doctors decide which patients are at low enough risk that they can be more conservatively managed.
In Genome Biology this week: computational tool to uncover cancer driver mutations, microbial species linked to ankylosing spondylitis, and more.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.